These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34552701)

  • 1. Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis.
    Yongpisarn T; Thimphitthaya C; Laoveeravat P; Wongjarupong N; Chaiteerakij R
    World J Hepatol; 2021 Aug; 13(8):949-968. PubMed ID: 34552701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.
    You MW; Kim KW; Shim JJ; Pyo J
    J Gastroenterol Hepatol; 2021 Mar; 36(3):601-608. PubMed ID: 32875681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
    Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
    Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.
    Ji D; Chen GF; Niu XX; Zhang M; Wang C; Shao Q; Wu V; Wang Y; Cheng G; Hurwitz SJ; Schinazi RF; Lau G
    Metabol Open; 2021 Jun; 10():100090. PubMed ID: 33889834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations of non-invasive tests for assessment of liver fibrosis.
    Patel K; Sebastiani G
    JHEP Rep; 2020 Apr; 2(2):100067. PubMed ID: 32118201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microRNA-1273g-3p is a useful non-invasive test for the prediction of liver fibrosis in patients with chronic hepatitis C.
    Nan Y; Niu X; Wang R; Zhao S; Fu N; Du J; Wang Y; Wang B; Zhang Y
    Exp Ther Med; 2019 Mar; 17(3):1817-1824. PubMed ID: 30783454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive tests for clinically significant portal hypertension after HCV cure.
    Semmler G; Lens S; Meyer EL; Baiges A; Alvardo-Tapias E; Llop E; Tellez L; Schwabl P; Mauro E; Escudé L; Díez C; Ibañez-Samaniego L; Puente Á; Fortea JI; Abadía M; Zanetto A; Conthe A; Hernandez-Évole H; Luzko Scheid IS; Jia J; Yoshiji H; Francque SM; Tsochatzis EA; Russo FP; Crespo G; Forns X; Bañares R; Villanueva C; Hernández-Gea V; Reiberger T; Bosch J; García Pagán JC; Mandorfer M;
    J Hepatol; 2022 Dec; 77(6):1573-1585. PubMed ID: 36063968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C.
    Vergniol J; Boursier J; Coutzac C; Bertrais S; Foucher J; Angel C; Chermak F; Hubert IF; Merrouche W; Oberti F; de Lédinghen V; Calès P
    Hepatology; 2014 Jul; 60(1):65-76. PubMed ID: 24519328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement.
    Tag-Adeen M; Sabra AM; Akazawa Y; Ohnita K; Nakao K
    Hepat Med; 2017; 9():45-53. PubMed ID: 29062242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients.
    Ferenci P; Aires R; Beavers KL; Curescu M; Abrão Ferreira PR; Gschwantler M; Ion S; Larrey D; Maticic M; Puoti M; Schuller J; Tornai I; Tusnádi A; Messinger D; Tatsch F; Horban A
    Hepatol Int; 2014 Jan; 8(1):83-93. PubMed ID: 26202409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy.
    Na SK; Lee SJ; Cho YK; Kim YN; Choi EK; Song BC
    J Interferon Cytokine Res; 2019 Nov; 39(11):703-710. PubMed ID: 31216229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive Assessment of Liver Fibrosis By Transient Elastography and FIB4/APRI for Prediction of Treatment Response in Chronic Hepatitis C-An Experience from a Tertiary Care Hospital.
    Taneja S; Tohra S; Duseja A; Dhiman RK; Chawla YK
    J Clin Exp Hepatol; 2016 Dec; 6(4):282-290. PubMed ID: 28003717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.
    Hsu WF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen HY; Wang HW; Huang GT; Peng CY
    BMC Gastroenterol; 2019 Apr; 19(1):63. PubMed ID: 31029101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis.
    Sahakyan Y; Lee-Kim V; Bremner KE; Bielecki JM; Krahn MD
    J Viral Hepat; 2021 May; 28(5):739-754. PubMed ID: 33556225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index and liver stiffness measurement in hepatitis B virus-infected patients with persistently normal alanine aminotransferase.
    Tan YW; Zhou XB; Ye Y; He C; Ge GH
    World J Gastroenterol; 2017 Aug; 23(31):5746-5754. PubMed ID: 28883700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation of liver stiffness measured by FibroTouch and FibroScan with Ishak fibrosis score in patients with chronic hepatitis B].
    Chen GF; Ping J; Gu HT; Zhao ZM; Zhou Y; Xing F; Tao YY; Mu YP; Liu P; Liu CH
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):145-150. PubMed ID: 28297803
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
    Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
    J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients.
    Wang CC; Liu CH; Lin CL; Wang PC; Tseng TC; Lin HH; Kao JH
    J Formos Med Assoc; 2015 Oct; 114(10):923-8. PubMed ID: 26279173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive Assessment of Liver Fibrosis Regression in Patients with Chronic Hepatitis B: A Retrospective Cohort Study.
    Xu W; Hu Q; Chen C; Li W; Li Q; Chen L
    Infect Dis Ther; 2023 Feb; 12(2):487-498. PubMed ID: 36520331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.